BACKGROUND. The eosinophilia-myalgia syndrome is a newly recognized illness that has been associated with the consumption of tryptophan products. It is not known whether the cause is related to the tryptophan itself or to chemical constituents introduced by the manufacturing process. METHODS. To describe the epidemiology of the eosinophilia-myalgia syndrome further and elucidate a possible association with the manufacturing process, we conducted surveillance for the syndrome in Minnesota, a community survey of tryptophan use in Minneapolis-St. Paul, and a case-control study to assess potential risk factors, including the use of tryptophan from different manufacturers. We performed high-performance liquid chromatography on tryptophan samples to identify other chemical constituents. RESULTS. The prevalence of tryptophan use increased from 1980 to 1989 and was highest among women. Among the subjects for whom the source of the tryptophan was known, 29 of 30 case patients (97 percent) and 21 of 35 controls (60 percent) had consumed tryptophan manufactured by a single company (odds ratio, 19.3; 95 percent confidence interval, 2.5 to 844.9; P less than 0.001). This company used a fermentation process involving Bacillus amyloliquefaciens to manufacture tryptophan. Analysis of the manufacturing conditions according to the retail lot demonstrated an association between lots used by case patients and the use of reduced quantities of powdered carbon in a purification step (odds ratio, 9.0; 95 percent confidence interval, 1.1 to 84.6; P = 0.014), as well as the use of a new strain of B. amyloliquefaciens (Strain V) (odds ratio, 6.0; 95 percent confidence interval, 0.8 to 51.8; P = 0.04). There was a significant correlation (r = 0.78, P less than 0.001) between the reduced amount of powdered carbon used during manufacturing and the use of the new bacterial strain. High-performance liquid chromatography of this company's tryptophan demonstrated one absorbance peak (peak E) that was present in 9 of the 12 retail lots (75 percent) used by patients and 3 of 11 lots (27 percent) used by controls (odds ratio, 8.0; 95 percent confidence interval, 0.9 to 76.6; P = 0.022). CONCLUSIONS. The outbreak of the eosinophilia-myalgia syndrome in 1989 resulted from the ingestion of a chemical constituent that was associated with specific tryptophan-manufacturing conditions at one company. The chemical constituent represented by peak E may contribute to the pathogenesis of the eosinophilia-myalgia syndrome, or it may be a surrogate for another chemical that induces the syndrome.
Source Information
Division of Field Services, Centers for Disease Control, Minneapolis, MN.
This article has been cited by other articles:
Mastaglia, F L
(2006). Drug induced myopathies. PN
6: 4-13
[Full Text]
Lanski, S. L., Greenwald, M., Perkins, A., Simon, H. K.
(2003). Herbal Therapy Use in a Pediatric Emergency Department Population: Expect the Unexpected. Pediatrics
111: 981-985
[Abstract][Full Text]
Hertzman, P. A., Clauw, D. J., Duffy, J., Medsger, T. A. Jr, Feinstein, A. R.
(2001). Rigorous New Approach to Constructing a Gold Standard for Validating New Diagnostic Criteria, as Exemplified by the Eosinophilia-Myalgia Syndrome. Arch Intern Med
161: 2301-2306
[Abstract][Full Text]
Anto, J.M., Cullinan, P.
(2001). Clusters, classification and epidemiology of interstitial lung diseases: concepts, methods and critical reflections. Eur Respir J
18: 101S-106s
[Abstract][Full Text]
Stahl, J. L., Cook, E. B., Pariza, M. A., Cook, M. E., Graziano, F. M.
(2001). Effect of L-Tryptophan Supplementation on Eosinophils and Eotaxin in Guinea Pigs. Exp. Biol. Med.
226: 177-184
[Abstract][Full Text]
Liepa, G.
(2001). Editorial: Cardioprotective Effects of {omega}-3 Fatty Acids: A Critical Review That Should Be Read by a Wide Range of Health Professionals. Nutr Clin Pract
16: 5-5
Sardesai, V. M., Myers, T.
(2001). Clinincal Observations: Nutrient Supplements in Clinical Care. Nutr Clin Pract
16: 35-45
[Abstract]
Donnay, A., Baker, G. P., Fardon, D. F., Garfin, S. R., Saal, J. A., Simon, G., Deyo, R. A., Sternberg, E. M., Gordon, D. A., Brodkin, C. A., Mohr, S., Frumkin, H., Marsh, D. J., Scott, H. D., Fulks, J. R., Kern, D. G., Durand, K. T.H.
(1997). Intimidation of Researchers by Special-Interest Groups. NEJM
337: 1314-1319
[Full Text]
Kaufman, L. D., Gleich, G. J.
(1997). The Expanding Clinical Spectrum of Multisystem Disease Associated With Eosinophilia. Arch Dermatol
133: 225-227
[Abstract]
Hennessy, T. W., Hedberg, C. W., Slutsker, L., White, K. E., Besser-Wiek, J. M., Moen, M. E., Feldman, J., Coleman, W. W., Edmonson, L. M., MacDonald, K. L., Osterholm, M. T., The Investigation Team,
(1996). A National Outbreak of Salmonella enteritidis Infections from Ice Cream. NEJM
334: 1281-1286
[Abstract][Full Text]
Sullivan, E. A., Kamb, M. L., Jones, J. L., Meyer, P., Philen, R. M., Falk, H., Sinks, T.
(1996). The Natural History of Eosinophilia-Myalgia Syndrome in a Tryptophan-Exposed Cohort in South Carolina. Arch Intern Med
156: 973-979
[Abstract]
Kaufman, L. D., Gruber, B. L., Gomez-Reino, J. J., Miller, F.
(1994). Fibrogenic Growth Factors in the Eosinophilia-Myalgia Syndrome and the Toxic Oil Syndrome. Arch Dermatol
130: 41-47
[Abstract]
Norden, M.
(1993). Risk of Tryptophan Depletion Following Amino Acid Supplementation. Arch Gen Psychiatry
50: 1000-1000
[Abstract]
Hatch, D. L., Goldman, L. R.
(1993). Reduced Severity of Eosinophilia-Myalgia Syndrome Associated With the Consumption of Vitamin-Containing Supplements Before Illness. Arch Intern Med
153: 2368-2373
[Abstract]
Kamb, M. L., Jones, J. L., Kilbourne, E. M., Falk, H.
(1993). Eosinophilia-Myalgia Syndrome or Fibromyalgia With Eosinophilia?-Reply. JAMA
269: 3108-3109
[Abstract]
Sternberg, E. M., Chrousos, G. P., Wilder, R. L., Gold, P. W.
(1992). The Stress Response and the Regulation of Inflammatory Disease. ANN INTERN MED
117: 854-866
[Abstract]
Lynn, J., Rammohan, K. W., Bornstein, R. A., Kissel, J. T.
(1992). Central Nervous System Involvement in the Eosinophilia-Myalgia Syndrome. Arch Neurol
49: 1082-1085
[Abstract]
Hedberg, K., Urbach, D., Slutsker, L., Matson, P., Fleming, D.
(1992). Eosinophilia-Myalgia Syndrome: Natural History in a Population-Based Cohort. Arch Intern Med
152: 1889-1892
[Abstract]
Varga, J., Uitto, J., Jimenez, S. A.
(1992). The Cause and Pathogenesis of the Eosinophilia-Myalgia Syndrome. ANN INTERN MED
116: 140-147
[Abstract]
Kamb, M. L., Murphy, J. J., Jones, J. L., Caston, J. C., Nederlof, K., Horney, L. F., Swygert, L. A., Falk, H., Kilbourne, E. M.
(1992). Eosinophilia-Myalgia Syndrome in L-Tryptophan--Exposed Patients. JAMA
267: 77-82
[Abstract]
Culpepper, R. C., Williams, R. G., Mease, P. J., Koepsell, T. D., Kobayashi, J. M.
(1991). Natural History of the Eosinophilia-Myalgia Syndrome. ANN INTERN MED
115: 437-442
[Abstract]
Blauvelt, A., Falanga, V.
(1991). Idiopathic and L-Tryptophan-Associated Eosinophilic Fasciitis Before and After L-Tryptophan Contamination. Arch Dermatol
127: 1159-1166
[Abstract]
Silver, R. M.
(1991). Unraveling the Eosinophilia-Myalgia Syndrome. Arch Dermatol
127: 1214-1216
[Abstract]
James, T. N., Kamb, M. L., Sandberg, G. A., Silver, R. M., Kilbourne, E. M.
(1991). Postmortem Studies of the Heart in Three Fatal Cases of the Eosinophilia-Myalgia Syndrome. ANN INTERN MED
115: 102-110
[Abstract]
Martinez-Osuna, P., Espinoza, L. R.
(1991). On the Treatment of the Eosinophilia-Myalgia Syndrome. Arch Intern Med
151: 1239-1239
[Abstract]
Lindgren, C.E., Walker, L. A., Bolton, P.
(1991). L-tryptophan Induced Eosinophilia-Myalgia Syndrome. The Journal of the Royal Society for the Promotion of Health
111: 29-30
Benjamin, D. M.
(1991). L-Tryptophan: A Pharmaceutical Detective Story. Journal of Pharmacy Practice
4: vi-x
Mayeno, A., Lin, F, Foote, C., Loegering, D., Ames, M., Hedberg, C., Gleich, G.
(1990). Characterization of "peak E," a novel amino acid associated with eosinophilia-myalgia syndrome. Science
250: 1707-1708
[Abstract]
Mayer, J. W.
(1990). Clarification of Contaminants in L-Tryptophan. ANN INTERN MED
113: 721-722
[Abstract]
(1990). Analysis of L-Tryptophan for the Etiology of Eosinophilia-Myalgia Syndrome. Arch Dermatol
126: 1274-1274
[Abstract]
LEWKONIA, R. M.
(1990). Myalgia and Eosinophilia Associated With Ingestion of Tryptophan: An Intriguing New Syndrome. Arch Intern Med
150: 2005-2007
[Abstract]
Strongwater, S. L., Woda, B. A., Yood, R. A., Rybak, M. E., Sargent, J., DeGirolami, U., Smith, T. W., Varnis, C., Allen, S., Murphy, K., Malhotra, R., Romain, P. L.
(1990). Eosinophilia-Myalgia Syndrome Associated With L-Tryptophan Ingestion: Analysis of Four Patients and Implications for Differential Diagnosis and Pathogenesis. Arch Intern Med
150: 2178-2186
[Abstract]
(1990). EOSINOPHILIA-MYALGIA SYNDROME WAS CAUSED BY CONTAMINATED TRYPTOPHAN. JWatch General
1990: 1-1
[Full Text]
